BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer

Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehmsen, Sidse, Pedersen, Rune M., Bang, Line L., Asmussen, Anders, Kragh, Amalie, Holm, Dorte K., Sydenham, Thomas V., Jensen, Thøger G., Jeppesen, Stefan S., Frederiksen, Henrik, Andersen, Thomas E., Ditzel, Henrik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910012/
https://www.ncbi.nlm.nih.gov/pubmed/36804967
http://dx.doi.org/10.1016/j.ccell.2023.02.003
Descripción
Sumario:Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with cancer.

Ejemplares similares